Anti-Epileptic Drug Targets Ewing Sarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ewing Sarcoma (ES) is a rare pediatric bone cancer driven by chromosomal translocations affecting gene expression.
• Current ES therapies have significant side effects, necessitating novel therapeutic strategies.
• Histone acetyl transferases (HATs) and histone deacetylases (HDACs) are key regulators of transcription.

Purpose of the Study:

• To investigate the molecular mechanism by which EWS-ERG/EWS-Fli-1 fusion proteins regulate RXRα transcriptional activity in ES.
• To evaluate valproic acid (VPA), an HDAC inhibitor, as a potential therapeutic agent for ES by reversing the inhibitory effects of the fusion protein.

Main Methods:

• Investigated the interaction between EWS-ERG/EWS-Fli-1 fusion proteins and RXRα transcriptional activity.
• Utilized valproic acid (VPA) to assess its impact on ES cell lines.
• Analyzed VPA's effects on cell growth, apoptosis, gene expression (RXRα target genes, fusion proteins), and p21 activity.

Main Results:

• EWS-ERG/EWS-Fli-1 fusion proteins inhibit RXRα transcriptional activity.
• VPA effectively reverses the inhibitory effect of EWS-ERG/EWS-Fli-1 on RXRα.
• VPA treatment inhibits ES cell growth, induces apoptosis, restores RXRα target gene expression, and represses fusion protein levels.

Conclusions:

• Aberrant fusion proteins in ES regulate HDACs-mediated repressor complexes, inhibiting RXRα activity.
• VPA demonstrates therapeutic potential by targeting the aberrant fusion protein's mechanism and inhibiting ES cell proliferation.
• VPA may offer a novel treatment strategy for ES, potentially reducing health disparities.